Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pRTP801-hVEGF
- Development stage
- Preclinical
- Lead developer
- Hallym University
- Modality
- Gene Therapies
- Administration
- Intramuscular, Subcutaneous, Parenteral
01
Overview
pRTP801-hVEGF is a hypoxia-inducible plasmid DNA gene therapy designed to express human vascular endothelial growth factor (hVEGF, specifically the VEGF-165 isoform) under the control of the hypoxia-responsive RTP801 promoter. It is developed for therapeutic angiogenesis to treat ischemic diseases, such as myocardial ischemia, myocardial infarction, and peripheral arterial disease, as well as to improve islet engraftment and survival in islet transplantation by promoting revascularization under hypoxic conditions. The plasmid is typically delivered using non-viral carriers such as water-soluble lipopolymer (WSLP) or Effectene.
- Other names
- hypoxia-inducible VEGF plasmidpRTP801-VEGF-165pRTP-801-VEGF-165pRTP 801-VEGF-165pRTP801-hVEGF165pRTP-801-hVEGF165pRTP 801-hVEGF165
Beyond the preview
Go deeper on pRTP801-hVEGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pRTP801-hVEGF.